← All trials
NCT04707261
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 6, 2021
- Primary completion
- Jan 1, 2024
- Completion date
- Jan 1, 2025
- First posted
- Jan 13, 2021
- Last posted
- Oct 28, 2021
- Enrollment
- 1990
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Xiangtan Central HospitalLead sponsor
- Central South UniversityStudy director
- Central South UniversityCollaborator
- Xiangtan Central HospitalReponsible party - principal investigator
- Xiangtan Central HospitalStudy chair
- ZhuZhou Central HospitalStudy director
- ZhuZhou Central HospitalCollaborator
- Xiangtan Central HospitalStudy director
- Xiangxiang People's HospitalStudy director
- The First People's Hospital of Xiangtan CityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.